$AST SpaceMobile, Inc.(ASTS)$  The space race is heating up, and investors are comparing the "execution king" Rocket Lab ($RKLB) with the "high-reward disruptor" AST SpaceMobile ($ASTS). With both companies reporting, here is the quick breakdown of the 2026 momentum:Rocket Lab ($RKLB): The Execution Leader.Commercial Win: Just reported record Q1 2026 revenue of $200.3 million (up 63.5% YoY).Backlog: Their massive $2.2 billion backlog proves they have steady, real-world demand from both government and commercial customers.Status: Moving toward profitability with a diversified business (launches + satellite parts).AST SpaceMobile ($ASTS): The High-Growth Wildcard.Commercial Pivot: Reported $70.9 million in 2025 revenue—a huge jump from their "p

The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\(LLY / \)NVO): They own the "gold standard" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from "knock-offs" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit

The healthcare sector is having a massive recovery, and everyone is asking: can Hims & Hers ($HIMS) actually keep pace with the giants like Eli Lilly ($LLY) and Novo Nordisk ($NVO)?Here’s the simple breakdown:The Giants (\(LLY / \)NVO): They own the "gold standard" drugs (Zepbound and Wegovy). Lilly is currently winning on growth, while Novo is adjusting to price changes.The Disruptor ($HIMS): They don’t make the drugs, but they own the access. They’ve pivoted from "knock-offs" to partnering directly with the big guys to sell brand-name GLP-1s.The Verdict: While Hims won't match their total billions in revenue, they can keep pace in growth percentage. They are betting that patients prefer a slick app experience over a traditional doctor's visit

w

Great analysis. It’s wild to see an 11% drop despite record revenue ($808.4M) and a massive operating margin expansion. With the $2 billion Nvidia investment now on the balance sheet, this feels more like a technical 'buy the news' pullback than a change in the AI narrative. I’m viewing this dip as a solid entry point for the long term

W

I am grateful for the current stock market situation as amidst the bleak looking market situation it is actually a chance for long term investor to havea chance to achieve generational wealth during this period

To allow commission free trades without any referral being done this is so done so that more investors would be enticed by tiger'a perks being given and hence attract even more investors to comeabroad tiger or from other brokerages.